Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

343
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
343
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

3.8K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
3.8K
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

645
Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
645
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

750
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
750
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

522
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
522

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reply on 'High-urgency heart transplantation and outcome trade-offs: early post-transplant infection and mortality'.

ESC heart failure·2026
Same author

Epigenetic Remodeling in Myocardial Reperfusion Injury: The Emerging Role of the ARID1A/SOX9 Axis.

Korean circulation journal·2026
Same author

From Risk Factors to Action: Preventing Stroke After Durable LVAD in the Contemporary Era.

Korean circulation journal·2026
Same author

Illuminating the Role of RNA Epigenetics in Abdominal Aortic Aneurysm: The Impact of YTHDF3 on Vascular Smooth Muscle Cell Fate.

Korean circulation journal·2026
Same author

High-urgency heart transplantation and outcome trade-offs: early post-transplant infection and mortality.

ESC heart failure·2026
Same author

Coronary Computed Tomographic Angiography Versus Functional Testing in Patients With Newly Diagnosed Type 2 Diabetes and Suspected Coronary Artery Disease: Real-world Evidence from the Nationwide Cohort.

Korean circulation journal·2026

Related Experiment Video

Updated: Apr 29, 2026

Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model
07:50

Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model

Published on: September 3, 2020

4.1K

Cell therapy for myocardial infarction.

Yoo-Wook Kwon1, Han-Mo Yang2, Hyun-Jai Cho2

  • 1Innovative Research Institute for Cell Therapy, Seoul National University Hospital, Seoul, Korea.

International Journal of Stem Cells
|May 24, 2014
PubMed
Summary
This summary is machine-generated.

Acute myocardial infarction (MI) causes significant mortality. Stem cell therapy shows promise for regenerating heart tissue, offering a potential new treatment strategy for MI patients with modest functional improvements.

Keywords:
Cell therapyIschemic heart diseaseMyocardial infarctionRegenerative medicineStem cells

More Related Videos

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix
09:11

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix

Published on: September 22, 2014

11.4K
Intramyocardial Cell Delivery: Observations in Murine Hearts
08:12

Intramyocardial Cell Delivery: Observations in Murine Hearts

Published on: January 24, 2014

13.1K

Related Experiment Videos

Last Updated: Apr 29, 2026

Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model
07:50

Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model

Published on: September 3, 2020

4.1K
Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix
09:11

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix

Published on: September 22, 2014

11.4K
Intramyocardial Cell Delivery: Observations in Murine Hearts
08:12

Intramyocardial Cell Delivery: Observations in Murine Hearts

Published on: January 24, 2014

13.1K

Area of Science:

  • Cardiology
  • Regenerative Medicine
  • Stem Cell Biology

Background:

  • Ischemic heart disease, especially acute myocardial infarction (MI), is a leading global cause of death.
  • Current treatments for MI, including PCI and medical therapies, have limitations in addressing myocardial cell loss and subsequent heart failure.
  • Stem and progenitor cell therapy has emerged as a promising strategy for cardiac regeneration after MI.

Purpose of the Study:

  • To review the pathogenesis of acute MI.
  • To discuss current MI treatments and their limitations.
  • To evaluate the clinical results and mechanisms of stem/progenitor cell therapy for MI.

Main Methods:

  • Literature review of studies on acute MI pathogenesis.
  • Analysis of current standard treatments for MI.
  • Review of clinical trial data on stem/progenitor cell therapy for MI.
  • Exploration of proposed mechanisms underlying cell therapy benefits.

Main Results:

  • Stem cell therapy for MI has demonstrated a favorable safety profile.
  • Clinical studies show modest improvements in cardiac function following stem cell therapy.
  • The exact mechanisms of benefit for stem cell therapy in MI are still under investigation.

Conclusions:

  • Despite advances, effective treatment for myocardial cell loss post-MI remains a challenge.
  • Stem and progenitor cell therapy represents a promising therapeutic avenue for MI.
  • Further research is needed to optimize cell therapy and elucidate its mechanisms for improved cardiac repair.